Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicifadine in Chronic Low Back Pain
NCT00295724Phase 3Completed
- Sponsor
- DOV Pharmaceutical, Inc.
- Start
- Oct 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chronic low back pain (CLBP) comparing Bicifadine 200 mg BID with Placebo (2 arms). Primary endpoint: Pain Severity Rating (Visual Analog Scale). Started Oct 2005; status: completed.
02
Drugs
bicifadine
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT00295724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295724.